Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.37 |
| ▸ | TMPRSS15 | P98073 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 3/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9906240 | 0.90 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2L3MBTL1PRSS1TMPRSS15 | |
| SCHEMBL9906250 | 0.83 | L3MBTL1 (0.38) | ALDH1A1SMN1; SMN2L3MBTL1RAB9AACE | |
| SCHEMBL9906239 | 0.74 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2L3MBTL1RAB9AACE | |
| SCHEMBL7811720 | 0.68 | RAB9A (0.57) | ALDH1A1SMN1; SMN2L3MBTL1RAB9AACE | |
| SCHEMBL3710312 | 0.68 | RAB9A (0.57) | ALDH1A1SMN1; SMN2L3MBTL1RAB9AACE | |
| SCHEMBL7815566 | 0.68 | RAB9A (0.57) | ALDH1A1SMN1; SMN2L3MBTL1RAB9AACE | |
| SCHEMBL9176416 | 0.68 | RAB9A (0.60) | ALDH1A1SMN1; SMN2L3MBTL1RAB9AACE | |
| SCHEMBL395833 | 0.66 | RAB9A (0.65) | ALDH1A1SMN1; SMN2RAB9AACEACE2 | |
| SCHEMBL9668555 | 0.66 | RAB9A (0.65) | ALDH1A1SMN1; SMN2RAB9AACEACE2 | |
| SCHEMBL2634067 | 0.64 | RAB9A (0.62) | ALDH1A1SMN1; SMN2L3MBTL1RAB9AACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130157986-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | INVASC THERAPEUTICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8198317-B2 | Methylenedioxy phenolic compounds and their use to treat disease | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100035849-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035849-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | REN, PCSK9, ALOX12 | ALDH1A1 787/4885SMN1; SMN2 2546/4885L3MBTL1 2073/4885 |
| US-20130157986-A1 | NOVEL METHYLENEDIOXY PHENOLIC COMPOUNDS AND THEIR USE TO TREAT DISEASE | REN, PCSK9, COMT | ALDH1A1 773/4885SMN1; SMN2 1684/4885L3MBTL1 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.